Black clients in expansion states who used opioids were more likely to access medication for opioid use disorder after ACA implementation.
暂无分享,去创建一个
[1] T. Winkelman,et al. Medicaid Expansion Increased Medications For Opioid Use Disorder Among Adults Referred By Criminal Justice Agencies. , 2021, Health affairs.
[2] R. Sadler,et al. African Americans now Outpace Whites in Opioid-Involved Overdose Deaths: A Comparison of Temporal Trends from 1999-2018. , 2020, Addiction.
[3] S. Comer,et al. Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorder , 2020, Substance abuse.
[4] Zachary F. Meisel,et al. Incidence of Treatment for Opioid Use Disorder Following Nonfatal Overdose in Commercially Insured Patients , 2020, JAMA network open.
[5] Rebecca J. Shlafer,et al. Medications for opioid use disorder among pregnant women referred by criminal justice agencies before and after Medicaid expansion: A retrospective study of admissions to treatment centers in the United States , 2020, PLoS medicine.
[6] B. Marshall,et al. Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States , 2020, JAMA network open.
[7] Darshak M Sanghavi,et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. , 2020, JAMA network open.
[8] C. Brayne,et al. Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17 , 2019, PloS one.
[9] D. Polsky,et al. Private Coverage of Methadone in Outpatient Treatment Programs. , 2019, Psychiatric services.
[10] K. Geissler,et al. Changes in Medicaid Acceptance by Substance Abuse Treatment Facilities After Implementation of Federal Parity , 2019, Medical care.
[11] P. Friedmann,et al. Medicaid coverage in substance use disorder treatment after the affordable care act. , 2019, Journal of substance abuse treatment.
[12] M. Olfson,et al. The Affordable Care Act and Opioid Agonist Therapy for Opioid Use Disorder. , 2019, Psychiatric services.
[13] K. Kozhimannil,et al. Substance use disorder treatment admissions and state-level prenatal substance use policies: Evidence from a national treatment database. , 2019, Addictive behaviors.
[14] C. MacLean,et al. The Effect of Public Insurance Expansions on Substance Use Disorder Treatment: Evidence from the Affordable Care Act , 2017, Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management].
[15] T. Land,et al. Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose. , 2020, Annals of emergency medicine.
[16] T. Wilens,et al. Opioid Use Disorders: Perioperative Management of a Special Population , 2018, Anesthesia and analgesia.
[17] Na Wang,et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality , 2018, Annals of Internal Medicine.
[18] Angélica Meinhofer,et al. The role of health insurance on treatment for opioid use disorders: Evidence from the Affordable Care Act Medicaid expansion. , 2018, Journal of health economics.
[19] K. Feder,et al. Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine. , 2017, Health affairs.
[20] Ryan M. McKenna. Treatment use, sources of payment, and financial barriers to treatment among individuals with opioid use disorder following the national implementation of the ACA. , 2017, Drug and alcohol dependence.
[21] K. Feder,et al. Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. , 2017, Drug and alcohol dependence.
[22] W. Gellad,et al. Medication-Assisted Treatment and Opioid Use Before and After Overdose in Pennsylvania Medicaid , 2017, JAMA.
[23] Fang Zhang,et al. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014 , 2017, JAMA pediatrics.
[24] B. Madras. The Surge of Opioid Use, Addiction, and Overdoses: Responsibility and Response of the US Health Care System. , 2017, JAMA psychiatry.
[25] B. Druss,et al. Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment , 2017, Medical care.
[26] C. Horgan,et al. Commercial Health Plan Coverage of Selected Treatments for Opioid Use Disorders from 2003 to 2014 , 2017, Journal of psychoactive drugs.
[27] He Zhu,et al. Treatment utilization among persons with opioid use disorder in the United States. , 2016, Drug and alcohol dependence.
[28] J. Morenoff,et al. Health Insurance Trends and Access to Behavioral Healthcare Among Justice-Involved Individuals—United States, 2008–2014 , 2016, Journal of General Internal Medicine.
[29] Astha Singhal,et al. Racial-Ethnic Disparities in Opioid Prescriptions at Emergency Department Visits for Conditions Commonly Associated with Prescription Drug Abuse , 2016, PloS one.
[30] H. Hansen,et al. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. , 2016, Drug and alcohol dependence.
[31] B. Anderson,et al. Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification. , 2016, Journal of substance abuse treatment.
[32] B. Cook,et al. Access To Mental Health Care Increased But Not For Substance Use, While Disparities Remain. , 2016, Health affairs.
[33] C. Barry,et al. Justice-Involved Adults With Substance Use Disorders: Coverage Increased But Rates Of Treatment Did Not In 2014. , 2016, Health affairs.
[34] J. Mennis,et al. Racial and Ethnic Disparities in Outpatient Substance Use Disorder Treatment Episode Completion for Different Substances. , 2016, Journal of substance abuse treatment.
[35] Colleen L Barry,et al. Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment. , 2016, Psychiatric services.
[36] Thomas R Frieden,et al. Medication-assisted therapies--tackling the opioid-overdose epidemic. , 2014, The New England journal of medicine.
[37] C. Welsh,et al. Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone. , 2014, Drug and alcohol dependence.
[38] W. Ling,et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. , 2014, Addiction.
[39] B. Saloner,et al. Blacks and Hispanics are less likely than whites to complete addiction treatment, largely due to socioeconomic factors. , 2013, Health affairs.
[40] K. Anderson,et al. Racial and ethnic disparities in pain: causes and consequences of unequal care. , 2009, The journal of pain : official journal of the American Pain Society.
[41] J. Bell,et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. , 2009, Drug and alcohol dependence.
[42] J. Strang,et al. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. , 2009, Journal of substance abuse treatment.
[43] Dingcai Cao,et al. Need-service matching in substance abuse treatment: racial/ethnic differences. , 2009, Evaluation and program planning.
[44] M. Connock,et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. , 2007, Health technology assessment.
[45] A. Kilbourne,et al. Advancing health disparities research within the health care system: a conceptual framework. , 2006, American journal of public health.
[46] Yongli Xi,et al. Increasing deaths from opioid analgesics in the United States , 2006, Pharmacoepidemiology and drug safety.